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A best evidence topic was written according to a structured protocol. The question addressed was
whether Heller’s myotomy provides superior results in comparison to botulinum toxin injection (BoTx)
for treatment of achalasia.
A total of 119 papers were retrieved using the reported searches of which 5 represented the best
evidence to answer the clinical question. The authors, date, journal, study type, population, main
outcome measures and results were tabulated. The highest level of evidence was one multicenter
randomised controlled trial. We concluded that Heller’s myotomy is superior to botulinum toxin injec-
tion for treatment of achalasia in terms of short and long term clinical outcome. Botulinum toxin
injection may be considered in older patients and in patients for whom an operation or pneumatic
dilation entails a higher risk, or as a bridge when these more effective modalities are not immediately
available. It has an excellent safety proﬁle and can be performed as a day case procedure.
 2012 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
A best evidence topic was constructed according to a structured
protocol. This protocol is fully described in the International Journal
of Surgery.12. Clinical scenario
Whilst in consultation with an achalasia patient, he states that
he recently read an article in the newspaper on the various medical
uses of botulinum toxin (BoTx). He then asks you if its use can spare
him the operation. You resolve to check the literature yourself.3. Three-part question
In [patients with achalasia] is [botulinum toxin injection] or
[Hellersmyotomy] themodalitywith thebest [treatmentoutcomes]?ry and Surgical Technology,
n W2 1NY, United Kingdom.
, e.zacharakis@imperial.ac.uk
ciates Ltd. Published by Elsevier Lt4. Search strategy
Search strategy using Medline from 1948 to November 2011
using the PubMed interface: Achalasia AND Botulinum toxin AND
Myotomy. Reference lists of key articles were also searched for
references.
5. Search outcome
A total of 121 papers were retrieved using the search strategy.
From these, 5 papers written in English were identiﬁed that
provided the best evidence to answer the question. These are
presented in Table 1.
6. Results
Zaninotto et al.2 conducted a prospective randomised trial of 80
newly diagnosed patients with achalasia between 18 and 75 years
of age (mean 50 years), without any previous endoscopic or surgical
treatment and ﬁt for surgery. Patients were randomised to either
botulinum toxin injection according to the protocol by Annese
et al.3 (n¼ 40) or laparoscopic Heller’s myotomy with anti-reﬂux
procedure (n¼ 40).d. All rights reserved.
Table 1
Best evidence papers.
Author, date and country,
study type (level of evidence)
Patient group Outcomes Key results Comment
Wang et al.4 2009
Digest Dis Sci
China
Meta-analysis of RCTs
(Level 1 evidence)
Meta-analysis of 17 RCTs including 761
patients. Authors searched electronic
databases (MEDLINE, EMBASE, Cochrane
Central Registry of Controlled Trials,
LILACS-Latin American, Caribbean health
science literature, and science citation
index expanded) for randomized
controlled trials assessing currently
available treatment options for achalasia.
Remission rate, relapse rate,
complications, and adverse effects were
included in the pooled data.
PD vs BoTx Heller’s Myotomy vs PD The authors conclude that PD is superior to
BoTx in respect of remission rate and
relapse rate, and that further comparison
of the PDwith laparoscopic myotomywith
the same outcome favours the surgical
treatment.
Complication rate did not differ
signiﬁcantly between PD and myotomy.
BoTx is the safest modality available.
Remission rate RR 2.20, 95% CI1.51
e3.20
RR 1.48, 95% CI 1.48
e1.87
Relapse rate RR 0.12, 95% CI 0.04
e0.32
RR 0.14, 95% CI 0.04
e0.58
Complications
Adverse events
RR 1.48, 95% CI 0.37
e5.99
Zaninotto et al.2 2004
Annals of Surgery
Italy
Multicenter prospective randomised
trial
(Level 2 evidence)
Eighty newly diagnosed patients with
achalasia were randomly assigned to BoTx
injection or laparoscopic myotomy.
Symptoms were scored (Eckardt score);
lower oesophageal sphincter resting and
nadir pressures were measured by
manometry; barium swallow was used to
assess oesophageal diameter pre- and
post-treatment.
Eighty to 100 units of BoTx were injected
twice, a month apart, at the
oesophagogastric junction.
Myotomy included anterior partial (Dor)
or Nissen fundoplication.
Heller’s myotomy (n¼ 40) vs. BoTx (n¼ 40) Better short and medium term results
with laparoscopic myotomy without
signiﬁcant difference in morbidity and
mortality.
The only prospective randomised trial
addressing this issue.
No predictive factor of good response
found at post hoc evaluation.
This study suggests that laparoscopic
myotomy is safe, offering better dysphagia
control, a greater reduction in symptom
scores and oesophageal obstruction (as
measured by manometry and barium
swallow) than BoTx. BoTx injection should
be recommended to patients unﬁt for
surgery or as a bridge to more effective
therapies such as myotomy or endoscopic
dilation.
Limitations: the use of the motorized
pull-through technique for evaluating
LES which is less accurate and thus
surpassed by the high resolution
manometry systems. Signiﬁcantly higher
resting LES pressures in the BotTx group.
Symptoms score Improvement at 6 months 82% (95% CI 76e89) vs
66% (95% CI 57-75), p< 0.05
Drop in LES pressure 78% vs 62% with nadir pressure <7 mmHg, p¼ n.s.
Reduction in oesophageal
diameter
19% (95% CI 13e26) vs 5% (95% CI 2e11), p< 0.05
Recurrence of symptoms Asymptomatic at 1 year 87% vs 60%
Likelihood of remaining asymptomatic at 2 years
87.5% vs 34%, p< 0.05.
Post-interventional reﬂux Non-signiﬁcant difference
Safety Nil mortality. Six days median hospital stay for
surgery. One surgical patient bled from the trocar
site requiring revisional surgery but no
transfusions.
Gutschow et al.7 2010
Langenbecks Arch Surg
Germany
Retrospective cohort study
(Level 3 evidence)
Forty-three patients with achalasia treated
in a single centre were analysed after
being grouped according to therapeutic
strategy: endoscopic botulinum toxin
injection (n¼ 7), endoscopic oesophageal
balloon dilatation (n¼ 16), surgical
myotomy after failed oesophageal balloon
dilatation (n¼ 14), and ﬁrst-line surgical
myotomy (n¼ 6). Themean follow-upwas
at 9, 35, 38, and 17 months respectively.
Efﬁcacy was assessed comparing
standardized symptom scores
preoperatively and at follow-up.
There was no signiﬁcant difference
BoTx vs PD vs Heller’s myotomy (after PD failure) vs
Heller’s myotomy
Surgery preferred as a ﬁrst line therapy
with BoTx suitable for use in exceptional
cases.
Limitations: Retrospective design, small
size, inhomogeneous follow-up periods,
single centre experience study.
Patients with Eckardt
symptoms score decrease
(median reduction)
28.6% (1.5) vs 93.8% (5.5) vs 64.3% (4) vs 83.3%
(6.5). For BoTx vs Heller’s myotomy p< 0.001
Relapse rate 71.4% vs 6.3% (50% if failures leading to myotomy
included) vs 35.7% vs 16.7%
Need for PPIs use 42.9% vs 12.5%vs 64.3% vs 33.3% (Heller’s myotomy
after failed PD vs PD p¼ 0.011. Between the other
three groups p¼ ns)
Mortality 0% vs 0% vs 0% vs 0%
Morbidity in number of
patients
0 vs 1 vs 1 vs 1 patients
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Table 1 (continued )
Author, date and country,
study type (level of evidence)
Patient group Outcomes Key results Comment
between the groups for age, sex, or
morbidity.
Vela et al.5 2004
Am J Gastroenterol
USA
Retrospective cohort study
(Level 3 evidence)
Retrospective analysis of 48 patients with
previous oesophageal surgery for
achalasia and 184 previously untreated
achalasia patients.
Patients underwent BoTx (n¼ 39, mean
age¼ 71), pneumatic dilatation (n¼ 111),
surgery (n¼ 72, 81% laparoscopic) or
combinations of the above between 1994
and 2002.
Symptoms, manometric and timed barium
oesophagram results, and treatments/
outcome determined.
Demographics: 232 patients evaluated,
mean age¼ 51, 51% male.
No previous treatment
(n¼ 184)
PD vs Heller’s myotomy vs BoTx Surgical treatment is favoured over Botox.
Limitations: retrospective study, short
follow-up (<1 y on average). Relatively
smaller number and older patients in the
BoTx arm (22 years older than the mean
age of the patients in the study,
p< 0.0001), non-standardised treatment.
Symptoms improvement 86% vs 89% (p¼ 0.63) vs 57% (p not reported e
improvement lasted for a mean 6.2 m, range
0e43 m)
Barium emptying study
improvement
54% vs 44% (p¼ 0.32) vs not reported
Perforation rate 2.7% vs N/A vs N/A
GORD requiring PPIs 16% vs 53% vs not reported (p< 0.001)
Requirement for additional
treatment
0% vs 0% vs 43%
Required oesophagectomy 3 (2%) overall
Prior surgery (n¼ 48) PD (n¼ 10) vs Redo myotomy (n¼ 21)
(8 patients required oesophagectomy)
Symptom improvement 67% vs 57% (p¼ 0.70)
Barium emptying study
improvement
11% vs 38% (p¼ 0.21)
Required oesophagectomy 8 (17%) overall
Andrew et al.6 1999
Surgical Endosc
Canada
Prospective patients choice study
(Level 3 evidence)
Prospective assessment of 22 achalasia
patients (15 men, 7 women; mean
age¼ 57.9 years).
Patients given a choice between BoTx
(n¼ 18) and myotomy (n¼ 4).
Oesophageal manometry, barium swallow
roentgenography, and dysphagia score
were assessed before and after treatment.
Myotomy vs BoTx Study highlights patients preference for
less invasive procedures.
Limitations: Small sample size, short
follow-up, patients choice study,
imbalance in numbers between study
groups.
Dysphagia score (0e10
range)
90 1.5 (in 6 months, p< 0.05) vs 70 2 (in
2 months, p< 0.01)
LOS nadir pressure (mmHg) 240 3 in 6 months (p<0.05) vs 220 15 in
2 months (p< 0.05)
Oesophageal barium
clearance (% of the 1 min
column retained at 5 min)
97%0 23% in 6 months (p< 0.05) vs 61%0 68%
in 2 months (p¼ 0.623)
PD, pneumatic dilatation; BoTx, botulinum toxin therapy; RCTs, randomised controlled trials; NS, not signiﬁcant; RR, relative risk.
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REVIEWSymptoms score improvement (Eckardt score), symptoms
recurrence, lower oesophageal sphincter resting and nadir pres-
sures and oesophageal diameter pre- and post-treatment were
assessed. It is the only prospective randomised trial addressing this
issue. Results favour surgery; 87% of patients in the myotomy group
remained asymptomatic one year after the operation and the
likelihood of remaining asymptomatic at 2 years was 87.5%. The
respective percentages in the BoTx group were 60% and 34%
(p< 0.05). Safety proﬁle and post-interventional gastro-oesopha-
geal reﬂux were not signiﬁcantly different between the two
modalities.
Weaknesses of the study comprise the use of the motorized
pull-through technique for the evaluation of the lower oesophageal
sphincter (LOS) which is less accurate than the current gold stan-
dard of high resolution manometry, and the signiﬁcantly higher
resting LOS pressures in the BoTx group.
The above conclusion is endorsed by the meta-analysis of
Wang et al. in 2009,4 when 17 RCTs involving 761 patients were
reviewed and analysed to evaluate which therapeutic measures
for achalasia are temporary and reversible and which measures
are deﬁnitive and effective. Pneumatic dilatation gave better
remission rate in comparison to botulinum toxin injection for
initial intervention [relative risk (RR) 2.20, 95% conﬁdence
interval (CI) 1.51e3.20] and lower relapse rate (RR 0.12, 95% CI
0.04e0.32). Compared with pneumatic dilatation, laparoscopic
myotomy further improved remission rate (RR 1.48, 95% CI
1.48e1.87), and reduced clinical relapse rate (RR 0.14, 95% CI
0.04e0.58), without a signiﬁcant increase in complication rate
(RR 1.48, 95% CI 0.37e5.99). Complications and adverse events
were essentially nil in the BoTx group. Despite a limited number
of randomized controlled trials the authors concluded that
laparoscopic myotomy is the preferred method for patients with
achalasia.
Vela et al.5 retrospectively reviewed 232 achalasia patients
presenting to a single oesophagologist at a tertiary referral centre,
in terms of treatment outcome and complexity. Forty-eight of
these patients had a previous oesophageal myotomy procedure
whilst 184 were previously untreated. Patients underwent
treatment with BoTx (n¼ 39), pneumatic dilatation (n¼ 111),
surgery (n¼ 72, 81% laparoscopic) or combinations of the above
between 1994 and 2002. They concluded that pneumatic dilata-
tion and Heller’s myotomy are the most effective treatments in
previously untreated patients. However, these modalities were
less successful in patients who had previous myotomy. Symptoms
and barium emptying improved in 86% and 54%, respectively in
the pneumatic dilatation group. Nineteen (17%) patients required
subsequent Heller myotomy (HM). The perforation rate was 2.7%.
In the myotomy group symptoms and barium emptying improved
in 89% and 44% respectively but there was greater proton pump
inhibitors (PPIs) use post-operatively (53%) and an anti-reﬂux
procedure did not decrease its incidence. Botulinum toxin injec-
tion led to symptomatic improvement in 57% of patients but lost
efﬁcacy within a mean of 6.2 months. There was need for
repeated injections (mean 1.7, range 1e7) and further treatment
with a different modality was required in 43% of patients. The
study was limited by the relatively smaller number (n¼ 39) and
the older age of patients in the BoTx arm (22 years more than the
mean in the study patients), short follow up (average <1 year),
non-standardised treatment modalities and retrospective study
design.
Andrew et al.6 prospectively assessed 22 achalasia patients
given a choice between BoTx and myotomy. Dysphagia score, LOSnadir pressure and timed barium oesophagogram were assessed.
The authors concluded that patients opted for less invasive
procedures, but surgery was more effective (7.5 vs 5 points drop
in dysphagia score, 21 vs 7 mmHg drop in LOS nadir pressure and
74% improvement vs 8% worsening in oesophageal barium
clearance test). The study was limited in terms of the small size,
short follow-up and that only 4 patients chose to enter the
surgery arm.
Gutschow et al.7 published a study describing a single centre’s
experience and included 43 patients divided into four groups
according to received treatment: BoTx (n¼ 7), PD (n¼ 16), myot-
omy after failed oesophageal balloon dilation (n¼ 14), and ﬁrst-
line surgical myotomy (n¼ 6). They concluded that surgical
myotomy should be the ﬁrst line treatment due to its superior
long-term clinical success rate (80% vs 50% after PD vs 28.6% after
BoTx). BoTx injection, in view of its high relapse rate (71.4%),
should be used in exceptional cases. The study was limited by the
small sample size, varied follow-up time and retrospective study
design.
7. Clinical bottom line
The existing evidence on the efﬁcacy and safety of botulinum
toxin therapy in comparison to laparoscopic Heller’s myotomy is
limited but appears convincing. Minimally invasive surgical treat-
mentwith the addition of an anti-reﬂux procedure is favoured as an
option since it offers long lasting improvement of symptoms in
a larger number of patients. However, botulinum toxin injection
may be safely considered in older patients and in patients for whom
an operation or pneumatic dilation entails a higher risk, or as
a bridge when these more effective modalities are not immediately
available.
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